CA19-9作为不可切除胰腺癌的预后因素：对临床试验的启示
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
作者信息
Maisey N R, Norman A R, Hill A, Massey A, Oates J, Cunningham D
机构信息
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
出版信息
Br J Cancer. 2005 Oct 3;93(7):740-3. doi: 10.1038/sj.bjc.6602760.
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3-2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS (HR 1.9; 95% CI: 1.1-3.4, P = 0.019).
在对154例接受化疗的患者进行的多变量分析中，基线CA19-9是总生存期（OS）的独立预后因素（风险比[HR] 1.8；95%置信区间[CI]：1.3 - 2.5，P = 0.0004）。基线CA19-9高于或低于中位数的患者，其1年总生存率分别为19%和46%。CA19-9水平较基线下降20%是总生存期的独立预后因素（风险比[HR] 1.9；95%置信区间[CI]：1.1 - 3.4，P = 0.019）。
Zotero 插件